BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies for liver disease and neurological disorders, has announced the offering of 4,443,000 shares of its Class A common stock. The shares are being offered at a price of $1.50 per share, pursuant to a prospectus supplement and the accompanying base prospectus. Concurrently, BioVie is also offering warrants to purchase up to 4,443,000 shares of its common stock in a private placement. Each warrant has an exercise price of $1.37 per share, exercisable six months after issuance, with a term of five years from the initial exercise date. The offering is being facilitated by ThinkEquity LLC, acting as the exclusive placement agent. The placement agent is not purchasing or selling any securities but has agreed to use its reasonable best efforts to arrange for the sale of the securities offered. The offering is expected to close on or about October 22, 2024, subject to customary closing conditions. The date of the prospectus supplement is October 21, 2024.

BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies for liver disease and neurological disorders, has announced the offering of 4,443,000 shares of its Class A common stock. The shares are being offered at a price of $1.50 per share, pursuant to a prospectus supplement and the accompanying base prospectus. Concurrently, BioVie is also offering warrants to purchase up to 4,443,000 shares of its common stock in a private placement. Each warrant has an exercise price of $1.37 per share, exercisable six months after issuance, with a term of five years from the initial exercise date. The offering is being facilitated by ThinkEquity LLC, acting as the exclusive placement agent. The placement agent is not purchasing or selling any securities but has agreed to use its reasonable best efforts to arrange for the sale of the securities offered. The offering is expected to close on or about October 22, 2024, subject to customary closing conditions. The date of the prospectus supplement is October 21, 2024.